Leverone Jason A.

Reported to SECin USFilings at 1 company

No score on this page, by design. These filings come from the American register (SEC). We show them as facts, with what the share price did since each filing and since each trade; our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings by this filer, out of 8. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are this filer’s key figures and the price change beside each line, since the filing and since the trade. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first. Reported is the day the filing reached the regulator, usually a few days after the trade itself.

5 of 8
Reported insider transactions
CompanyTypeValueReportedCompanyValueTypeSharesReported
OnKure Therapeutics, Inc.Chief Financial OfficerOpen-market sell$898302 sharesSep 23, 2026OnKure Therapeutics, Inc.Chief Financial Officer$898Sell · Sep 23Open-market sell302Sep 23, 2026
OnKure Therapeutics, Inc.Chief Financial OfficerAward—130,611 sharesAug 11, 2026OnKure Therapeutics, Inc.Chief Financial Officer—Award · Aug 11Award130,611Aug 11, 2026
OnKure Therapeutics, Inc.Chief Financial OfficerReturned to the issuer—130,611 sharesAug 11, 2026OnKure Therapeutics, Inc.Chief Financial Officer—Returned · Aug 11Returned to the issuer130,611Aug 11, 2026
OnKure Therapeutics, Inc.Chief Financial OfficerAward—5,322 sharesAug 11, 2026OnKure Therapeutics, Inc.Chief Financial Officer—Award · Aug 11Award5,322Aug 11, 2026
OnKure Therapeutics, Inc.Chief Financial OfficerReturned to the issuer—5,322 sharesAug 11, 2026OnKure Therapeutics, Inc.Chief Financial Officer—Returned · Aug 11Returned to the issuer5,322Aug 11, 2026